Breast Cancer/canceronco.com
Jan 20, 2025, 13:32
Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared an article by Charles E. Geyer on X:
“Data from KATHERINE trial confirms T-DM1 improves OS & sustains IDFS in HER2+ early Breast Cancer with residual disease after neoadjuvant therapy.
- 7-year IDFS: 80.8% (T-DM1)67.1% (trastuzumab)
- 7-year OS: 89.1% (T-DM1)84.4% (trastuzumab)
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Authors: Charles E. Geyer, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 21, 2025, 15:31
Jan 21, 2025, 15:31
Jan 21, 2025, 15:31
Jan 21, 2025, 15:31
Jan 21, 2025, 15:31
Jan 21, 2025, 15:31